<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824382</url>
  </required_header>
  <id_info>
    <org_study_id>1222.22</org_study_id>
    <nct_id>NCT00824382</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL Delivered by the Respimat Inhaler in Japanese Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
      inhalation solution delivered by the Respimat inhaler once daily for 4 weeks in Japanese
      patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum
      dose(s) will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic
      evaluations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 Response at Week 4</measure>
    <time_frame>baseline and after 4 weeks treatment</time_frame>
    <description>The change from baseline in trough FEV1 after 4 weeks of treatment. Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to next test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline . Baseline trough FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 prior to administration of the first dose of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response at Week 2</measure>
    <time_frame>baseline and after 2 weeks treatment</time_frame>
    <description>Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to next test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline trough FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 prior to administration of the first dose of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3) Response at 4 Weeks</measure>
    <time_frame>baseline and after 4 weeks treatment</time_frame>
    <description>The change from baseline in FEV1 AUC(0-3) after 4 weeks of treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in liters.
Due to normalization the unit is liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Peak(0-3) Response at 4 Weeks</measure>
    <time_frame>baseline and after 4 weeks treatment</time_frame>
    <description>The change from baseline in FEV1 peak(0-3) after 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response at Week 4</measure>
    <time_frame>baseline and after 4 weeks treatment</time_frame>
    <description>The change from baseline in Trough FVC after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-3) Response</measure>
    <time_frame>baseline and after 4 weeks treatment</time_frame>
    <description>The change from baseline in FVC AUC(0-3) response after 4 weeks of treatment. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in liters.
Due to normalization the unit is liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak(0-3) Response</measure>
    <time_frame>baseline and after 4 weeks treatment</time_frame>
    <description>The change from baseline in FVC peak(0-3) response after 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 0-6h (AUC 0-6h) Response After 4 Weeks</measure>
    <time_frame>baseline and after 4weeks treatment</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect.
FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 4 Weeks</measure>
    <time_frame>Baseline and after 4weeks treatment</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect.
FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR) After 4 Weeks</measure>
    <time_frame>Week 4</time_frame>
    <description>PEFR measurements were recorded by means of a patient diary on a daily basis. This diary was used to record the twice daily PEFs,
Morning measurements were performed immediately upon arising before administration of trial and/or rescue medication.The highest of three readings for each measurement were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Evening PEFR After 4 Weeks</measure>
    <time_frame>Week 4</time_frame>
    <description>PEFR measurements were recorded by means of a patient diary on a daily basis. This diary was used to record the twice daily PEFs,
Evening measurements were performed at bedtime.The highest of three readings for each measurement were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks</measure>
    <time_frame>Week 4</time_frame>
    <description>Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis, ECG and Physical Examination</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis, ECG and Physical examination. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference From Baseline in Potassium</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Difference from baseline in Potassium (normalized values). Normalization means that the values from different laboratories are transformed in such a way that they are directly comparable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum Measured Concentration of the Analyte in Plasma)</measure>
    <time_frame>after first inhalated administration</time_frame>
    <description>Cmax only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters,thus not applicable for the Olodaterol 2 mcg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (Maximum Measured Concentration of the Analyte in Plasma at Steady State)</measure>
    <time_frame>visit at week 4</time_frame>
    <description>Cmax,ss only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters, thus not applicable for the Olodaterol 2 mcg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-1</measure>
    <time_frame>after first inhalated administration</time_frame>
    <description>Area under the concentration curve from 0 to 1 hour using trapezoid rule, only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters,thus not applicable for Olodaterol 2mcg group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-1,ss</measure>
    <time_frame>visit at week 4</time_frame>
    <description>Area under the concentration curve from 0 to 1 hour at steady state using trapezoid rule, only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters, thus not applicable for Olodaterol 2mcg group</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>BI 1744 CL 5 Âµg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 puffs of 2.5 Âµg/actuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1744 CL 10 Âµg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 puffs of 5 Âµg/actuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 puffs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1744 CL 2 Âµg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 puffs of 1 Âµg/actuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL 2 Âµg</intervention_name>
    <description>2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler</description>
    <arm_group_label>BI 1744 CL 2 Âµg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL 5 Âµg</intervention_name>
    <description>2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler</description>
    <arm_group_label>BI 1744 CL 5 Âµg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL 10 Âµg</intervention_name>
    <description>2 puffs of 5 Âµg/actuation delivered by RespimatÂ®</description>
    <arm_group_label>BI 1744 CL 10 Âµg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 puffs delivered by the RespimatÂ® inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must sign an informed consent consistent with GCP guidelines prior to
             participation in the trial.

          2. All patients must have a diagnosis of chronic obstructive pulmonary disease and must
             meet the following spirometric criteria: Patients must have relatively stable,
             moderate to severe airway obstruction with a post-bronchodilator FEV1 &gt;=30% of
             predicted normal and &lt;80% of predicted normal and a post-bronchodilator FEV1/FVC &lt;70%
             at Visit 1

          3. Male or female patients, 40 years of age or older

          4. Patients must be current or ex-smokers with a smoking history of more than 10
             pack-years. Pack-Years = [Number of cigarettes/day/20] — years of smoking Patients who
             have never smoked cigarettes must be excluded.

          5. Patients must be able to perform technically acceptable pulmonary function tests (both
             supervised and unsupervised) and PEFR measurements, and must be able to record a
             patient diary during the study period as required in the protocol.

          6. Patients must be able to inhale medication in a competent manner from the Respimat
             inhaler and from a MDI.

        Exclusion Criteria:

          1. Patients with a significant disease other than COPD; a significant disease is defined
             as a disease which, in the opinion of the investigator, may i) put the patient at risk
             because of participation in the study ii) influence the results of the study, or iii)
             cause concern regarding the patient's ability to participate in the study

          2. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis; all patients with an AST &gt;80 IU/L, ALT &gt;80 IU/L, bilirubin &gt;1.5 x ULN or
             creatinine &gt;1.5 x ULN will be excluded regardless of clinical condition (a repeat
             laboratory evaluation will not be conducted in these patients)

          3. Patients with a history of asthma or a total blood eosinophil count &gt;=600/mm3. A
             repeat eosinophil count will not be conducted in these patients

          4. Patients with any of the following conditions:

               -  a diagnosis of thyrotoxicosis

               -  a diagnosis of paroxysmal tachycardia (&gt;100 beats per minute)

               -  a marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of
                  a QTc interval &gt;450 ms) as recommended by ICH E14. For patients who have a QTc
                  interval between 450 ms and 500 ms, as judged by site personnel, there will be a
                  confirmatory reading by centralized evaluation institute. If the confirmatory
                  reading is still greater than 450 ms, patient will be excluded. Patients with a
                  QTc interval &gt;=500 ms will immediately be excluded from the study.

               -  a history of additional risk factors for Torsade de Pointes (TdP) (e.g. heart
                  failure, hypokalemia, family history of Long QT Syndrome) as recommended by ICH
                  E14.

          5. Patients with any of the following conditions:

               -  a history of myocardial infarction within 1 year

               -  a diagnosis of clinically relevant cardiac arrhythmia

               -  known active tuberculosis

               -  a malignancy for which patient has undergone resection, radiation therapy or
                  chemotherapy within last 5 years (patients with treated basal cell carcinoma are
                  allowed)

               -  a history of life-threatening pulmonary obstruction

               -  a history of cystic fibrosis

               -  clinically evident bronchiectasis

               -  a history of significant alcohol or drug abuse

          6. Patients who have undergone thoracotomy with pulmonary resection (patients with a
             history of thoracotomy for other reasons should be evaluated as per exclusion
             criterion No. 1)

          7. Patients being treated with any of the following concomitant medications:

               -  medications that prolong the QT/QTc interval

               -  oral beta-adrenergics and beta-adrenergics patchs

               -  beta-blockers (topical beta-blockers for ocular conditions are allowed)

               -  oral corticosteroid medication at unstable doses (i.e. less than 6 weeks on a
                  stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per
                  day or 20 mg every other day.

          8. Patients who regularly use daytime oxygen therapy for more than 1 hour per day and in
             the investigator's opinion will be unable to abstain from the use of oxygen therapy
             during clinic visits

          9. Patients who have completed a pulmonary rehabilitation program in the 6 weeks prior to
             the screening visit (Visit 1) or patients who are currently in a pulmonary
             rehabilitation program

         10. Patients who have taken an investigational drug within 1 month or 6 half lives
             (whichever is greater) prior to screening visit

         11. Patients with known hypersensitivity to beta-adrenergics drugs, BAC, EDTA or any other
             component of the Respimat inhalation solution delivery system

         12. Pregnant or suspect of pregnant or women who are willing to become pregnant during the
             study period or nursing women

         13. Patients who have previously been participated in this study or are currently
             participating in another study

         14. Patients who are unable to comply with pulmonary medication restrictions prior to
             randomisation

         15. The randomization of patients with any respiratory infection or COPD exacerbation in
             the 6 weeks prior to the screening visit or during the screening period should be
             postponed. Patients may be randomised 6 weeks following recovery from the infection or
             exacerbation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.22.048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahikawa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachi, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inashiki-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamogawa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwada, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakyusyu, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koga, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komaki, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niigata, Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obihiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka-sayama, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Oasaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sashima-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seto, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shibata-gun, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takarazuka, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsukuba, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ube, Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uji, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wakayama, Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamagata, Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yao, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.22.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>May 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2014</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was enrolled in the trial on 13 January 2009 and the last patient made the last visit on 31 March 2010. A total of 515 patients were enrolled in the trial at 48 trial sites. Of the 515 patients, 328 patients were entered in the trial and were randomly assigned to receive either one of the four treatments for 4 weeks.</recruitment_details>
      <pre_assignment_details>Informed consent was obtained prior to patient participation in the trial, which included medication washout procedures or restrictions. Upon obtaining consent, the patients were instructed on the medication washout and other restrictions for the screening PFT (Visit 1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>Olodaterol 2mcg</title>
          <description>Olodaterol 2mcg inhalation solution via Respimat</description>
        </group>
        <group group_id="P3">
          <title>Olodaterol 5mcg</title>
          <description>Olodaterol 5mcg inhalation solution via Respimat</description>
        </group>
        <group group_id="P4">
          <title>Olodaterol 10mcg</title>
          <description>Olodaterol 10mcg inhalation solution via Respimat</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The treated set consisting of all randomised patients for whitch at least one investigational treatment was used.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>Olodaterol 2mcg</title>
          <description>Olodaterol 2mcg inhalation solution via Respimat</description>
        </group>
        <group group_id="B3">
          <title>Olodaterol 5mcg</title>
          <description>Olodaterol 5mcg inhalation solution via Respimat</description>
        </group>
        <group group_id="B4">
          <title>Olodaterol 10mcg</title>
          <description>Olodaterol 10mcg inhalation solution via Respimat</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="79"/>
            <count group_id="B4" value="86"/>
            <count group_id="B5" value="328"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.9" spread="6.5"/>
                    <measurement group_id="B2" value="68.9" spread="7.6"/>
                    <measurement group_id="B3" value="70.1" spread="6.7"/>
                    <measurement group_id="B4" value="69.3" spread="7.4"/>
                    <measurement group_id="B5" value="69.3" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent predicted normal FEV1</title>
          <description>Based on Japanese equation</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.64" spread="12.32"/>
                    <measurement group_id="B2" value="51.36" spread="14.15"/>
                    <measurement group_id="B3" value="52.07" spread="12.82"/>
                    <measurement group_id="B4" value="51.73" spread="11.81"/>
                    <measurement group_id="B5" value="51.45" spread="12.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent predicted normal FEV1</title>
          <description>based on Japanese equation</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to &lt; 50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50% to 80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response at Week 4</title>
        <description>The change from baseline in trough FEV1 after 4 weeks of treatment. Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to next test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline . Baseline trough FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 prior to administration of the first dose of study medication.</description>
        <time_frame>baseline and after 4 weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 4</title>
          <description>The change from baseline in trough FEV1 after 4 weeks of treatment. Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to next test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline . Baseline trough FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 prior to administration of the first dose of study medication.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.032" spread="0.015"/>
                    <measurement group_id="O2" value="0.059" spread="0.015"/>
                    <measurement group_id="O3" value="0.100" spread="0.015"/>
                    <measurement group_id="O4" value="0.100" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 2mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 5mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.172</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 10mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.172</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response at Week 2</title>
        <description>Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to next test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline trough FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 prior to administration of the first dose of study medication</description>
        <time_frame>baseline and after 2 weeks treatment</time_frame>
        <population>The full analysis set (FAS) - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response at Week 2</title>
          <description>Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to next test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline trough FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 prior to administration of the first dose of study medication</description>
          <population>The full analysis set (FAS) - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.016"/>
                    <measurement group_id="O2" value="0.061" spread="0.015"/>
                    <measurement group_id="O3" value="0.120" spread="0.016"/>
                    <measurement group_id="O4" value="0.136" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.081</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.124</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.115</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3) Response at 4 Weeks</title>
        <description>The change from baseline in FEV1 AUC(0-3) after 4 weeks of treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in liters.
Due to normalization the unit is liters.</description>
        <time_frame>baseline and after 4 weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3) Response at 4 Weeks</title>
          <description>The change from baseline in FEV1 AUC(0-3) after 4 weeks of treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in liters.
Due to normalization the unit is liters.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.017"/>
                    <measurement group_id="O2" value="0.118" spread="0.016"/>
                    <measurement group_id="O3" value="0.177" spread="0.017"/>
                    <measurement group_id="O4" value="0.173" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 2mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 5mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.197</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>0.241</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 10mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.193</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Peak(0-3) Response at 4 Weeks</title>
        <description>The change from baseline in FEV1 peak(0-3) after 4 weeks of treatment.</description>
        <time_frame>baseline and after 4 weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Peak(0-3) Response at 4 Weeks</title>
          <description>The change from baseline in FEV1 peak(0-3) after 4 weeks of treatment.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.017"/>
                    <measurement group_id="O2" value="0.170" spread="0.017"/>
                    <measurement group_id="O3" value="0.227" spread="0.017"/>
                    <measurement group_id="O4" value="0.220" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 2mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.146</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 5mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.202</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.157</ci_lower_limit>
            <ci_upper_limit>0.247</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 10mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.240</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response at Week 4</title>
        <description>The change from baseline in Trough FVC after 4 weeks of treatment</description>
        <time_frame>baseline and after 4 weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response at Week 4</title>
          <description>The change from baseline in Trough FVC after 4 weeks of treatment</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.033"/>
                    <measurement group_id="O2" value="0.154" spread="0.032"/>
                    <measurement group_id="O3" value="0.154" spread="0.033"/>
                    <measurement group_id="O4" value="0.150" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 2mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.275</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 5mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>0.276</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 10mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.187</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.270</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-3) Response</title>
        <description>The change from baseline in FVC AUC(0-3) response after 4 weeks of treatment. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in liters.
Due to normalization the unit is liters.</description>
        <time_frame>baseline and after 4 weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-3) Response</title>
          <description>The change from baseline in FVC AUC(0-3) response after 4 weeks of treatment. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in liters.
Due to normalization the unit is liters.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.036"/>
                    <measurement group_id="O2" value="0.257" spread="0.035"/>
                    <measurement group_id="O3" value="0.254" spread="0.036"/>
                    <measurement group_id="O4" value="0.237" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 2mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.253</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.160</ci_lower_limit>
            <ci_upper_limit>0.345</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 5mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.250</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.343</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 10mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.233</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.141</ci_lower_limit>
            <ci_upper_limit>0.325</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak(0-3) Response</title>
        <description>The change from baseline in FVC peak(0-3) response after 4 weeks of treatment.</description>
        <time_frame>baseline and after 4 weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak(0-3) Response</title>
          <description>The change from baseline in FVC peak(0-3) response after 4 weeks of treatment.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.109" spread="0.038"/>
                    <measurement group_id="O2" value="0.362" spread="0.037"/>
                    <measurement group_id="O3" value="0.351" spread="0.038"/>
                    <measurement group_id="O4" value="0.335" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 2mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.253</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.155</ci_lower_limit>
            <ci_upper_limit>0.351</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 5mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.242</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.142</ci_lower_limit>
            <ci_upper_limit>0.341</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Olodaterol 10mcg - Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean for the difference</param_type>
            <param_value>0.226</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.129</ci_lower_limit>
            <ci_upper_limit>0.324</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 0-6h (AUC 0-6h) Response After 4 Weeks</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect.
FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in liters.</description>
        <time_frame>baseline and after 4weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 0-6h (AUC 0-6h) Response After 4 Weeks</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect.
FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in liters.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.028"/>
                    <measurement group_id="O2" value="0.090" spread="0.027"/>
                    <measurement group_id="O3" value="0.195" spread="0.027"/>
                    <measurement group_id="O4" value="0.195" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.216</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.140</ci_lower_limit>
            <ci_upper_limit>0.293</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.217</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.142</ci_lower_limit>
            <ci_upper_limit>0.292</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 4 Weeks</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect.
FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in liters.</description>
        <time_frame>Baseline and after 4weeks treatment</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 4 Weeks</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a model with treatment (trt), baseline as fixed effects and centre as random effect.
FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in liters.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.028"/>
                    <measurement group_id="O2" value="0.078" spread="0.027"/>
                    <measurement group_id="O3" value="0.171" spread="0.027"/>
                    <measurement group_id="O4" value="0.186" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0348</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.100</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.190</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.115</ci_lower_limit>
            <ci_upper_limit>0.265</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR) After 4 Weeks</title>
        <description>PEFR measurements were recorded by means of a patient diary on a daily basis. This diary was used to record the twice daily PEFs,
Morning measurements were performed immediately upon arising before administration of trial and/or rescue medication.The highest of three readings for each measurement were recorded.</description>
        <time_frame>Week 4</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR) After 4 Weeks</title>
          <description>PEFR measurements were recorded by means of a patient diary on a daily basis. This diary was used to record the twice daily PEFs,
Morning measurements were performed immediately upon arising before administration of trial and/or rescue medication.The highest of three readings for each measurement were recorded.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
          <units>Liter/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.54" spread="4.059"/>
                    <measurement group_id="O2" value="244.80" spread="3.933"/>
                    <measurement group_id="O3" value="246.93" spread="4.059"/>
                    <measurement group_id="O4" value="254.22" spread="3.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.256</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.476</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.477</ci_lower_limit>
            <ci_upper_limit>38.036</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.383</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.574</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>18.410</ci_lower_limit>
            <ci_upper_limit>40.357</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>36.678</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.431</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.987</ci_lower_limit>
            <ci_upper_limit>47.369</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Evening PEFR After 4 Weeks</title>
        <description>PEFR measurements were recorded by means of a patient diary on a daily basis. This diary was used to record the twice daily PEFs,
Evening measurements were performed at bedtime.The highest of three readings for each measurement were recorded.</description>
        <time_frame>Week 4</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Evening PEFR After 4 Weeks</title>
          <description>PEFR measurements were recorded by means of a patient diary on a daily basis. This diary was used to record the twice daily PEFs,
Evening measurements were performed at bedtime.The highest of three readings for each measurement were recorded.</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
          <units>Liter/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.39" spread="4.085"/>
                    <measurement group_id="O2" value="256.44" spread="3.955"/>
                    <measurement group_id="O3" value="258.34" spread="4.083"/>
                    <measurement group_id="O4" value="264.58" spread="3.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.052</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.534</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>18.159</ci_lower_limit>
            <ci_upper_limit>39.946</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.955</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.635</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>19.861</ci_lower_limit>
            <ci_upper_limit>42.049</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>37.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.489</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>26.386</ci_lower_limit>
            <ci_upper_limit>47.996</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks</title>
        <description>Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol )</description>
        <time_frame>Week 4</time_frame>
        <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks</title>
          <description>Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol )</description>
          <population>The full analysis set (FAS) for 4 weeks treatment period which is however restricted to patients with evaluable data for this endpoint - analysis with imputation</population>
          <units>Number of puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.778" spread="0.110"/>
                    <measurement group_id="O2" value="0.587" spread="0.107"/>
                    <measurement group_id="O3" value="0.324" spread="0.109"/>
                    <measurement group_id="O4" value="0.392" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2016</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.149</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.485</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.454</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.151</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.752</ci_lower_limit>
            <ci_upper_limit>-0.156</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on an analysis of covariance with terms for baseline, treatment and center (center random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.387</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.148</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.678</ci_lower_limit>
            <ci_upper_limit>-0.095</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis, ECG and Physical Examination</title>
        <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis, ECG and Physical examination. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
        <time_frame>4 weeks</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis, ECG and Physical Examination</title>
          <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis, ECG and Physical examination. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
          <population>Treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrioventricular block second degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood lactate dehydrogenase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference From Baseline in Potassium</title>
        <description>Difference from baseline in Potassium (normalized values). Normalization means that the values from different laboratories are transformed in such a way that they are directly comparable.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 2mcg</title>
            <description>Olodaterol 2mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O3">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O4">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Difference From Baseline in Potassium</title>
          <description>Difference from baseline in Potassium (normalized values). Normalization means that the values from different laboratories are transformed in such a way that they are directly comparable.</description>
          <population>Treated set.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.6"/>
                    <measurement group_id="O3" value="-0.0" spread="0.5"/>
                    <measurement group_id="O4" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Maximum Measured Concentration of the Analyte in Plasma)</title>
        <description>Cmax only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters,thus not applicable for the Olodaterol 2 mcg</description>
        <time_frame>after first inhalated administration</time_frame>
        <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Measured Concentration of the Analyte in Plasma)</title>
          <description>Cmax only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters,thus not applicable for the Olodaterol 2 mcg</description>
          <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="46.7"/>
                    <measurement group_id="O2" value="8.22" spread="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss (Maximum Measured Concentration of the Analyte in Plasma at Steady State)</title>
        <description>Cmax,ss only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters, thus not applicable for the Olodaterol 2 mcg</description>
        <time_frame>visit at week 4</time_frame>
        <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss (Maximum Measured Concentration of the Analyte in Plasma at Steady State)</title>
          <description>Cmax,ss only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters, thus not applicable for the Olodaterol 2 mcg</description>
          <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" spread="57.4"/>
                    <measurement group_id="O2" value="13.1" spread="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-1</title>
        <description>Area under the concentration curve from 0 to 1 hour using trapezoid rule, only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters,thus not applicable for Olodaterol 2mcg group</description>
        <time_frame>after first inhalated administration</time_frame>
        <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-1</title>
          <description>Area under the concentration curve from 0 to 1 hour using trapezoid rule, only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters,thus not applicable for Olodaterol 2mcg group</description>
          <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="35.6"/>
                    <measurement group_id="O2" value="6.08" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-1,ss</title>
        <description>Area under the concentration curve from 0 to 1 hour at steady state using trapezoid rule, only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters, thus not applicable for Olodaterol 2mcg group</description>
        <time_frame>visit at week 4</time_frame>
        <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol 5mcg</title>
            <description>Olodaterol 5mcg inhalation solution via Respimat</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol 10mcg</title>
            <description>Olodaterol 10mcg inhalation solution via Respimat</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-1,ss</title>
          <description>Area under the concentration curve from 0 to 1 hour at steady state using trapezoid rule, only calculated if &gt;1/3 of the patients have available pharmacokinetic parameters, thus not applicable for Olodaterol 2mcg group</description>
          <population>Treated set which is however restricted to patients with evaluable data for this endpoint (Patients in which all plasma concentration values were below limit of quantification (BLQ), were excluded from the analysis and were not included into the total number of participants affected for this outcome measure)</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="54.6"/>
                    <measurement group_id="O2" value="10.8" spread="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Olodaterol 2mcg</title>
          <description>Olodaterol 2mcg inhalation solution via Respimat</description>
        </group>
        <group group_id="E3">
          <title>Olodaterol 5mcg</title>
          <description>Olodaterol 5mcg inhalation solution via Respimat</description>
        </group>
        <group group_id="E4">
          <title>Olodaterol 10mcg</title>
          <description>Olodaterol 10mcg inhalation solution via Respimat</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

